YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 557-563

  Batinic, Klaudija ^a,b   Höbaus, Clemens ^b   Grujicic, Milan ^b   Steffan, Angelika ^b   Jelic, Finka ^b   Lorant, David ^b   Hörtenhuber, Thomas ^b   Hoellerl, Florian ^b,c   Brix, Johanna Maria ^c   Schernthaner, Guntram ^c   Koppensteiner, Renate ^b   Schernthaner, Gerit Holger ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Peripheral artery disease; Type 2 diabetes mellitus; YKL 40

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BINDING PROTEIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; YKL 40 PROTEIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; AGED; AUSTRIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PREDIABETIC STATE; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84861343040     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.034     Document Type: Article

References (35)

1. Millis A.J., Hoyle M., Reich E., Mann D.M. Isolation and characterization of a Mr=38.000 protein from differentiating smooth muscle cells. J Biol Chem 1985, 260:3754-3761.
2. Vos K., Steenbakkers P., Miltenburg A.M., et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000, 59:544-548.
3. Volck B., Price P.A., Johansen J.S., et al. YKL-40, a mammalian member of the bacterial chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998, 110:351-360.
4. Johansen J.S., Bojesen S.E., Mylin A.K., et al. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009, 27:572-578.
5. Johansen J.S., Christoffersen P., Møller S., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920.
6. Rehli M., Niller H.H., Ammon C., et al. Transcriptional regulation of CHI3L1, a marker for late stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067.
7. Boot R.G., van Achterberg T.A., van Aken B.E., et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and cartilage gp-39 expression in lesion macrophages. Arterioscler Thromb Vasc Biol 1999, 19:687-694.
8. Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003, 287:79-87.
9. Kucur M., Isman F.K., Karadag B., Vural V.A., Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007, 18:391-396.
10. Wang Y., Ripa R.S., Johansen J.S., et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008, 42:295-302.
11. Nøjgaard C., Høst N.B., Christensen I.J., et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008, 19:257-263.
12. Mathiasen A.B., Harutyunyan M.J., Jørgensen E., et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011, 71:439-444.
13. Zheng J.L., Lu L., Hu J., et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 2010, 21:590-595.
14. Mygind N.D., Harutyunyan M.J., Mathiasen A.B., et al. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011, 60:281-287.
15. Kastrup J., Johansen J.S., Winkel P., et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009, 30:1066-1072.
16. Kjaergaard A.D., Bojesen S.E., Johansen J.S., Nordestgaard B.G. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010, 68:672-680.
17. Rathcke C.N., Johansen J.S., Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patient with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006, 55:53-59.
18. Nielsen A.R., Erikstrup C., Johansen J.S., et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008, 57:3078-3082.
19. Rathcke C.N., Persson F., Tarnow L., Rossing P., Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009, 32:323-328.
20. Schaller G., Brix J., Placher-Sorko G., et al. YKL-40 concentrations are not elevated in gestational diabetes. Eur J Clin Invest 2010, 40(4):339-343.
21. Hempen M., Kopp H.P., Elhenicky M., et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009, 19:1557-1563.
22. Hoertenhuber T., Hoellerl F., Hoebaus C., et al. YKL-40 is elevated in type 1 diabetic children which show components of metabolic syndrome compared to those without, as well as to healthy control subjects. Diabetologia 2009, 52:S1-S345.
23. Brix J.M., Hoellerl F., Koppensteiner R., Schernthaner G., Schernthaner G.H. YKL-40 in type 2 diabetic patients with different levels of albuminuria. Eur J Clin Invest 2011, 41:589-596.
24. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):S1-S75.
25. Kallio M., Forsblom C., Groop P.H., Groop L., Lepantalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 2003, 26:1241-1245.
26. Report of a WHO consultation. In: Alwan A, King H, editors. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance; 1999. p. 1-59. http://www.who.int/.
27. Lorant D.P., Grujicic M., Hoebaus C., et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care 2011, 34(Jan (1)):156-161.
28. Ridker P.M., Hennekens C.H., Buring J., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
29. Rothman K., Greenland S. Modern epidemiology 1998, Lippincott Williams & Wilkins, Philadelphia.
30. Thomsen S.B., Rathcke C.N., Zerahn B., Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010, 9:86.
31. Fach E.M., Garulacan L.A., Gao J., et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004, 3:1200-1210.
32. Barr E., Zimmet P., Welborn T., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. Circulation 2007, 116:151-157.
33. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
34. Hermans M.M., Henry R.M., Dekker J.M., et al. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens 2008 Apr, 26(4):791-797.
35. Demer L.L., Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008, 117(22):2938-2948.